Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Byotrol in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 0.10.
Current Consensus is
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in Byotrol. This N/A consensus rating has held steady for over two years.
Byotrol plc develops and commercialize antimicrobial technologies and products in the United Kingdom, North America, and internationally. The company operates through Professional and Consumer segments. Its product portfolio includes Actizone, a antimicrobial technology which improves cleaning performance and long-lasting protection against bacteria; and Byotrol, a long-lasting antimicrobial protection for various applications including bathroom cleaners to multi-surface wipes. The company also offers HLD4, a broad-spectrum disinfectant designed for high soil environments of the animal health sector; and Invirtu for skin care. It serves human and animal health, facilities management, food and beverages, household, and skin and pet care markets. The company was incorporated in 2005 and is headquartered in Chester, the United Kingdom.
Read More
